578 KB49 KB200420252022Rajčević, UrošSmole, Anžeštevilka:4letnik:59str. 173-184DOI:10.26873/SVR-1513-2022COBISSID_HOST:142663939ISSN:1580-4003URN:URN:NBN:SI:doc-PBZVCPE5enZaložba Univerze v LjubljaniSlovenian veterinary researchCell- and Tissue-Based TherapyHeterograftsMicePreclinical mouse models in adoptive cell therapies of cancer|Engineered T cell-based therapies are an advanced approach for cancer immunotherapy using genetically modi- fied T cells. To date, CD19 and BCMA targeting Chimeric Antigen Receptor (CAR) T cells have been approved for the treatment of certain hematologic malignancies. The success of CAR-T cells is offset by limited efficacy, particularly in solid tumors, and safety risks. Preclinical in vivo research, which is highly dependent on reliable mouse models, has been a cornerstone of the suc- cess story of adoptive cell therapies and continues to provide invaluable information for the development of the next generation of cellular immunotherapies. In this review we describe four of the most common preclinical mouse models: xenograft models, syngeneic models, immunocompetent transgenic models and humanized mouse models. All of these have advantages and disadvantages and no mouse model can fully recapitulate the human situation because of inherent differences and treatment complexity. Reports suggest that using a combination of mouse models in preclinical in vivo research prior to translating the treat- ment to humans in clinical trials can help incrementally improve the quality, safety, and efficacy of the treatment and provide more comprehensive information than a single modelTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaUniverza v Ljubljani, Veterinarska fakulteta